Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

275.13 +1.12 (+0.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 714,018
Open 275.73
Bid (Size) 271.51 (1)
Ask (Size) 279.04 (1)
Prev. Close 274.01
Today's Range 272.64 - 276.38
52wk Range 187.16 - 311.88
Shares Outstanding 144,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
From Biogen Inc.
Via Globe NewsWire
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
From Biogen Inc.
Via Globe NewsWire

Performance

YTD
+0.92%
+0.92%
1 Month
+2.20%
+2.20%
3 Month
+0.40%
+0.40%
6 Month
-0.54%
-0.54%
1 Year
+28.00%
+28.00%

More News

Read More
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
From Biogen Inc.
Via Globe NewsWire
Biogen Unusual Options Activity
Via Benzinga
11 Analysts Have This to Say About Biogen
Via Benzinga
7 Blue-Chip Stocks Sitting in the Sweet Spot
Via InvestorPlace
Elliott Wave Technical Analysis: Biogen Inc. - Thursday, March 23
Via Talk Markets
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
Via Investor's Business Daily
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder
Via Benzinga
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
From Biogen Inc.
Via Globe NewsWire
Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit
Via Benzinga
Should You Buy Biogen Before a Big July Decision?
Via The Motley Fool
Price Over Earnings Overview: Biogen
Via Benzinga
iMetabolic BioPharma's Alzheimer's Disease Therapeutic Innovation Is A Breakthrough Three-Pronged Approach
Via Benzinga
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
Via InvestorPlace
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo
Via Benzinga
(BIIB) - Analyzing Biogen's Short Interest
Via Benzinga
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
Via Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
Via Benzinga
Biogen's Debt Overview
Via Benzinga
1 Reason to Buy Biogen Stock, and 1 Reason to Sell
Via The Motley Fool
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
From Biogen Inc.
Via Globe NewsWire
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
Via FinancialNewsMedia
Exposures COVID-19
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
Via Benzinga
Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
Via MarketBeat
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.